INTERVENTIONALUNKNOWNNCT04042545

SAFETY AND EFFICACY OF PPP001-kit FOR THE UNCONTROLLED PAIN RELIEF IN PATIENTS WITH ADVANCED CANCER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY

This phase 2 multicenter clinical trial assess the safety and efficacy of inhaled PPP001 to relieve the pain in 78 advanced cancer patients with uncontrolled symptoms. This is a 4-week treatment period study followed by an open label period of 1 year.

Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2021-09-16

What this record can show

Protocol only - no registry results posted

This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.

Registry facts

Study at a glance

Phase: PHASE2
Enrollment: 78 (ESTIMATED)
Start date: 2020-07-30
Sponsor: Tetra Bio-Pharma
Design: RANDOMIZED · PARALLEL · TREATMENT
Locations: 1
Results record: Not present in registry snapshot

This is a 4-week randomized, double-blind, placebo-controlled, parallel group design trial to evaluate the safety and efficacy of inhaled PPP001 on uncontrolled cancer pain in patients with symptoms related to advanced incurable cancer.

Linked local records

Related local records

Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.

Conditions

Cancer Pain

Cannabinoids and active compounds

No governed compound link was found.

Medicines

No exact medicine-name link was found.

Interventions

What was registered

DRUG

PPP001

1 cannabis dosing capsule inhaled 3 times a day with a vaporizer device

QIXLEEF

DRUG

Placebo

1 placebo dosing capsule inhaled 3 times a day with a vaporizer device

Eligibility

Population and criteria

Sex: ALL
Minimum age: 18 Years
Maximum age: Not reported
Healthy volunteers: Not accepted

Inclusion criteria

1. Written informed consent, 2. Adult male and female patients at least 18 years of age, 3. Subject agreed to follow the protocol, 4. Advanced cancer for which there is no known curative therapy as per investigator's judgement, 5. Patients experiencing at least 2 symptoms related to cancer \> 4 on ESAS-r-CS NRS including pain symptom, 6. Life expectancy six weeks or longer with PPS \> 50% and PaP Score Group A (30-day survival probability \>70%), 7. No cognitive impairment according to Mini-Cog©, 8. The patient is able to perform deep inhalations with FEV1 more than 60%, 9. Ability to read and respond to questions in English, 10. A female volunteer must meet one of the following criteria: If of childbearing potential - agrees to use one of the accepted contraceptive regimens from at least 28 days prior to the first drug administration, during the study and for at least 60 days after the last dose, If of non-childbearing potential - should be surgically sterile or in a menopausal state, 11. A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must be surgically sterile or agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration.

primary outcomes

primary measures

Uncontrolled cancer pain will be measured using a patient self-administered questionnaire.

Time frame: change from baseline in the EORTC-QLQ-C15-PAL pain multi-item scale score at Week 4.

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 Palliative (EORTC-QLQ-C15-PAL). items are rated on a scale of 1 (not at all) to 4 (very much). high scores on a symptom scale correlate to increased symptom burden

secondary outcomes

secondary measures

The overall HRQoL (Health related Quality of Life) of patients with uncontrolled symptoms related to advanced cancer will be measured using a patient self rating questionnaire.

Time frame: change from baseline in the EORTC-QLQ-C15-PAL overall QoL single-item scale score at Week 4

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 15 Palliative (EORTC-QLQ-C15-PAL). single-item scale is rated from 1 (very poor) to 7 (excellent). High scores on a functional scale correspond to better functioning

The physical, emotional, and total symptom distress will be measured using a patient self administered questionnaire.

Time frame: Change from Baseline in ESAS-r-CS at Weeks 1 and 4

Revised Edmonton Symptom Assessment System (ESAS-r-CS). 11 core symptoms: pain, tiredness, nausea, depression, anxious, drowsiness, appetite, feeling of well-being, shortness of breath, constipation and trouble sleeping. 11-point NRS ranging from 0 (no symptom) to 10 (worst possible).

The palliative performance scale will be scored by a healthcare profesional.

Time frame: Change from Baseline in PPS at Weeks 1 and 4

palliative performance scale version 2 (PPSv2) for measuring functional status in end-of-life patients. A healthcare professional scores each dimension by assigning a value from 100% to 0% (death), with 10% denoting the lowest level of functioning

The satisfaction of family caregivers of patients with advanced cancer will be measured using a caregiver self administered questionnaire.

Time frame: Change from Baseline in treatment-satisfaction questionnaire at Weeks 1 and 4

The treatment satisfaction questionnaire (change version) will be used. Scale range is a left to right 7-item scale for caregiver. each item is scored from 5 (Much more satisfied now) to 1 (Much Less satisfied now).

The distress of patients with advanced cancer will be measured using a patient self-administered questionnaire

Time frame: Change from Baseline in distress thermometer at Week 4

Publications

Locally readable linked articles

No exact PMID-linked public article is currently readable locally.

Snapshot provenance

Snapshot: 009e1856-4ace-49d5-ac4e-92b495b8a238
Retrieved: 11/09/2026, 14:14:52
SHA-256: 2f1d6d63723f5407508751b0800543fbcd4a19bc241453b1ead6b3a939a6c31b